BridgeBio has published results from its pivotal Phase 3 Propel [...]
As Rare Disease Day 2026 highlights the challenges faced by [...]
Ascendis Pharma UK Limited announced that TransCon CNP (navepegritide) has [...]
Tyra Biosciences has dosed the first child in BEACH301, its [...]